Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integrated BiopharmaINBP 36 Days Payable is 22.45 as of Mar. 2026, which is 24% below its 10-year median of 29.53. GuruFocus rates INBP with a GF Score™ of 36/100 and a GF Value™ of $0.26 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,893 Consumer Packaged Goods companies, Integrated Biopharma ranks worse than 84.42% on this metric.
The historical rank and industry rank for Integrated Biopharma's Days Payable or its related term are showing as below:
INBP'
s Days Payable Range Over the Past 10 Years
Min: 17.87 Med: 29.53 Max: 52.78
Current: 20.11
During the past 13 years, Integrated Biopharma's highest Days Payable was 52.78. The lowest was 17.87. And the median was 29.53.
INBP's Days Payable is ranked worse than 84.42% of 1893
companies
in the Consumer Packaged Goods industry
Industry Median: 43.96
vs INBP: 20.11
Integrated Biopharma's Days Payable
increased
from Mar. 2025 (19.54) to Mar. 2026 (22.45).
It may suggest that Integrated Biopharmadelayed paying its suppliers.
The historical data trend for Integrated Biopharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Integrated Biopharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Biopharma Days Payable vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Integrated Biopharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Integrated Biopharma's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Biopharma (INBP) has a Days Payable of 22.45 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Integrated Biopharma and its competitors. This is 24% below median its historical median of 29.53. Over the past decade, Integrated Biopharma's Days Payable has ranged from 17.87 to 52.78. According to the industry distribution chart, Integrated Biopharma ranks #1598 out of 1893 companies in the Consumer Packaged Goods industry, placing it in the top 84.4%.
Is Integrated Biopharma's Days Payable too high?
Integrated Biopharma's current Days Payable of 22.45 is 24% below median its 10-year median of 29.53. Over the past 10 years, this metric has ranged from a low of 17.87 to a high of 52.78. The Consumer Packaged Goods industry median Days Payable is 43.96. Integrated Biopharma's value of 22.45 is 48.9% below this industry median. Based on the distribution chart, Integrated Biopharma ranks #1598 out of 1893 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Integrated Biopharma has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrated Biopharma's Days Payable compare to HCWC and PAVS?
According to the Consumer Packaged Goods industry distribution chart, Integrated Biopharma ranks #1598 out of 1893 companies for Days Payable. This places Integrated Biopharma in the lower half of its industry. The industry median Days Payable is 43.96. Integrated Biopharma's value of 22.45 is 48.9% below this benchmark. Historically, Integrated Biopharma's own Days Payable has ranged from 17.87 to 52.78 over the past decade. While the company's 10-year median is 29.53 vs. the industry median of 43.96, Integrated Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Consumer Packaged Goods company?
The median Days Payable among Consumer Packaged Goods companies is 43.96, based on 1,893 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integrated Biopharma's current Days Payable of 22.45 is 48.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Integrated Biopharma and its competitors. For the Consumer Packaged Goods industry, the median Days Payable is 43.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrated Biopharma's current Days Payable is 22.45, which is 24% below median its own 10-year median of 29.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Integrated Biopharma (INBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.26, compared to a current price of $0.16 — trading 38.5% below its estimated fair value. The current Days Payable is 22.45, which is 24% below median its 10-year median of 29.53 and 48.9% below the Consumer Packaged Goods industry median of 43.96. Integrated Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Integrated Biopharma (INBP), the current Days Payable is 22.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Biopharma (INBP) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Biopharma stock appears to be undervalued.
The current stock price of $0.16 is trading 38.5% below its estimated GF Value™ of $0.26.
GuruFocus considers Integrated Biopharma to be Possible Value Trap.
Key valuation signals for INBP:
Days Payable: 22.45 (24% below median its 10-year median of 29.53)
GF Value™: $0.26 vs. price of $0.16 (38.5% below fair value)
Industry Position: 48.9% below the Consumer Packaged Goods median (#1598 of 1893)
No single metric tells the full story. See the INBP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments: Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from the Contract Manufacturing segment, which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers.
36GF Score
Get the complete analysis for INBP
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBP has been successfully added to your 
